Biohaven (BHVN) drew investor attention after its stock rose 12.66% as the company outlined plans to start pivotal clinical studies for several cancer and autoimmune candidates in its pipeline.

Looking beyond the latest jump, Biohaven’s share price return has been strong over shorter periods, with a 20.3% 7 day and 43.6% 30 day move. However, the 1 year total shareholder return declined 6.2%, which suggests recent momentum is rebuilding after a weaker stretch.

If you are looking for other high growth stories in healthcare and beyond, this is a good moment to scan the market for potential opportunities using our 40 healthcare AI stocks

With Biohaven’s shares rebounding sharply but longer term returns still weaker, the key question now is whether the recent optimism leaves the stock undervalued or if the market is already pricing in much of the potential pipeline progress.

Preferred Price-to-Book Multiple of 15.8x: Is It Justified?

On the latest data, Biohaven trades on a P/B of 15.8x, which places a steep valuation on the stock relative to both its own fundamentals and peers.

The P/B multiple compares the company’s market value to its book value of equity. A higher figure usually reflects strong profitability, asset quality, or expectations of future value creation. In Biohaven’s case, the company reports a loss of $647.677m, is currently unprofitable, and is not forecast to achieve profitability over the next 3 years, so that elevated multiple is not backed by current earnings.

Compared with the US Biotechs industry average P/B of 2.5x and a peer average of 3.5x, Biohaven’s 15.8x stands out as very expensive. This suggests the market is assigning a sizeable premium for the company’s pipeline and forecast revenue growth rather than its current balance sheet and income statement.

Result: Price-to-book of 15.8x (OVERVALUED)

However, Biohaven’s loss of $647.677m and its 3 year total shareholder return, which declined 41.5%, highlight execution and funding risks if clinical results or timelines disappoint.

Next Steps

With mixed signals around Biohaven’s valuation and outlook, it makes sense to move quickly and review the full risk reward picture yourself using the 1 key reward and 5 important warning signs.

Looking for more investment ideas beyond Biohaven?

If you are serious about finding the next opportunity, do not stop at Biohaven. Use focused stock lists to uncover ideas that match your goals faster.

• Explore potential mispriced opportunities by scanning the market for quality stocks trading below what their fundamentals might suggest with the 45 high quality undervalued stocks.
• Emphasize resilience by focusing on companies that combine financial strength with sensible fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).
• Identify early stage opportunities that still meet strict financial criteria by filtering for higher quality ideas within the 24 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.